Richard Hughes, Louise Whitley, Kocho Fitovski, Hans-Martin Schneble, Erwan Muros, Annette Sauter, Licinio Craveiro, Paul Dillon, Ulrike Bonati, Nikki Jessop, Rosetta Pedotti, Harold Koendgen
BACKGROUND: There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on people with multiple sclerosis (MS). OBJECTIVE: To better understand SARS-CoV-2 infection in ocrelizumab-treated people with MS. METHODS: Internal Roche/Genentech data sources: Cases of COVID-19 from ongoing Roche/Genentech clinical trials and from post-marketing use of ocrelizumab until July 31, 2020 were identified and assessed using descriptive statistics...
December 30, 2020: Multiple Sclerosis and related Disorders
Asya Izraelit Wallach, Maria J Borja, Duan Chen, Rachel Eisenberg, Yasha S Modi, Cen Zhang, Timothy M Shepherd, Avindra Nath, Bryan Smith, Jose U Scher, Catherine Cho, Ilya Kister
Recurrent episodes of neurological dysfunction and white matter lesions in a young adult raise suspicion for multiple sclerosis (MS). However, occlusive retinopathy, hearing loss and absence of CSF oligoclonal bands are atypical for MS and should make the clinician consider an alternative diagnosis. We describe a man with hearing loss, visual signs and symptoms, and an accumulating burden of brain lesions, who was treated for a clinical diagnosis of MS for nearly two decades. Genetic testing revealed a unifying diagnosis...
January 19, 2021: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
Yue Jia, Dandan Zhang, Haoran Li, Shaolei Luo, Yuhuan Xiao, Li Han, Fuchun Zhou, Chuanyue Wang, Lei Feng, Gang Wang, Peng Wu, Chunjie Xiao, Haijing Yu, Jing Du, Hongkun Bao
Multiple sclerosis (MS), as an inflammatory demyelinating disorder of central nervous system, is the leading cause of non-traumatic neurologic disability in young adults. The pathogenesis of MS remains unknown, however, a dysregulation of glia-neuroimmune signaling plays a key role during progressive disease stage. Most of the existing drugs are aimed at the immune system, but there is no approved drug by promoting remyelination after demyelination so far. There is a great interest in identifying novel agents for treating MS bytargeting to switch the immune imbalance from pro-inflammation and apoptosis to anti-inflammation and regeneration during remyelination phase...
January 19, 2021: Biochemical Pharmacology
Deborah K Johnson, Kaylia M Reynolds, Brian D Poole, Matthew D Montierth, Vera M Todd, April Barnado, Mary F Davis
Patients with autoimmune disorders (AD) have altered cancer risks compared to the general population. Systemic lupus erythematosus and multiple sclerosis lead to a heightened risk for hematological malignancies and decreased risk for breast, ovarian, and prostate malignancies. Often patients with autoimmune disease have dysregulated antiviral immune responses, including against oncogenic viruses. To uncover the relationship between viral incidence and cancer risk in the context of autoimmune disease, we extracted electronic health records (EHR) from Vanderbilt University...
2021: PloS One
F A Panizzolo, S Cimino, E Pettenello, A Belfiore, N Petrone, G Marcolin
Severe neurodegenerative diseases such as Parkinson's disease or multiple sclerosis and acute events like stroke, spinal cord injuries or other related pathologies have been shown to negatively impact the central and peripheral nervous systems, thus causing severe impairments to mobility. The development and utilisation of exoskeletons as rehabilitation devices has shown good potential for improving patients' gait function. Ten older adults (age: 68.9 ± 9.2 yrs; height: 1.65 ± 0.08 m. mass: 71.6 ± 11.0 kg) affected by neurological diseases impacting their gait function completed a 10-session gait training protocol where they walked for 10 minutes wearing a passive exoskeleton assisting hip flexion, namely Exoband...
January 22, 2021: Assistive Technology: the Official Journal of RESNA
Alessandra D'Amico, Teresa Perillo, Carmela Russo, Lorenzo Ugga, Daniela Melis, Claudia Santoro, Giulio Piluso, Giuseppe Cinalli
Tuberous sclerosis complex (TSC) is an autosomal dominant condition clinically presenting with heterogenous clinical features. Multiple neuroradiological manifestations have been associated with TSC, such as tubers, radial migration lines, subependymal nodules, subependymal giant cell astrocytomas, and cyst-like lesions of the white matter (CLLWMs). The latter have been described as non-enhancing well-defined cysts whose pathogenesis is still unknown. We describe 2 TSC patients with CLLWM showing contrast enhancement after Gadolinium injection, a previously unreported entity...
January 22, 2021: Neuroradiology
C L de Mol, A L Bruijstens, P R Jansen, Mhg Dremmen, Yym Wong, A van der Lugt, Tjh White, R F Neuteboom
BACKGROUND: Radiologically isolated syndrome (RIS) is typified by multiple sclerosis (MS)-like lesions on imaging, without clinical MS symptoms. The prevalence of pediatric RIS is largely unknown. OBJECTIVE: The objective of the study is to provide an estimated RIS prevalence in a population-based cohort of children. METHODS: We used data from the Generation R study to identify the childhood RIS prevalence. RESULTS: In 5238 participants, only one RIS case was identified (prevalence: 0...
January 22, 2021: Multiple Sclerosis: Clinical and Laboratory Research
Sahil Naik, Nivedita Jha, Shivani Naik, Steven Lippmann
No abstract text is available yet for this article.
January 21, 2021: Primary Care Companion to CNS Disorders
Saeed Sadigh-Eteghad, Negin Abbasi Garravnd, Mahsa Feizollahi, Mahnaz Talebi
BACKGROUND AND PURPOSE: Cognitive impairment (CI) is a common symptom of multiple sclerosis (MS). Although demographic and clinical factors contribute to MS-dependent CI, previous findings have been inconsistent. This study aimed to identify the cognitive domains that are impaired in MS patients, and to determine the impacts of the Expanded Disability Status Scale (EDSS) score and other clinical and demographic factors on them domains. METHODS: This study enrolled 115 MS patients...
January 2021: Journal of Clinical Neurology
Maria Pia Sormani, Nicola De Rossi, Irene Schiavetti, Luca Carmisciano, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli, Marco Capobianco, Maria Trojano, Paola Zaratin, Gioacchino Tedeschi, Giancarlo Comi, Mario Alberto Battaglia, Francesco Patti, Marco Salvetti
OBJECTIVE: To assess the impact of immunosuppressive and immunomodulatory therapies on the severity of Coronavirus disease 2019 (Covid-19) in people with MS (PwMS). METHODS: We retrospectively collected data of PwMS with suspected or confirmed Covid-19. All the patients had complete follow up to death or recovery. Severe Covid-19 was defined by a 3-level variable: mild disease not requiring hospitalization vs pneumonia or hospitalization vs Intensive Care Unit (ICU) admission or death...
January 21, 2021: Annals of Neurology
Bing Han, Yan-Yan Zhang, Ze-Qing Ye, Yun Xiao, Javad Rasouli, Wen-Cheng Wu, Su-Min Ye, Xin-Yue Guo, Lin Zhu, Abdolmohamad Rostami, Li-Bin Wang, Yuan Zhang, Xing Li
Montelukast is a leukotriene receptor antagonist that is known to prevent allergic rhinitis and asthma. Blocking the Cysteinyl leukotrienes receptor (CysLTR1), one of the primary receptors of leukotrienes, has been demonstrated to be efficacious in ameliorating experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), through disrupting chemotaxis of infiltrating T cells. However, the role of CysLTR1 in the pathogenesis of MS is not well understood. Here, we show that MS patients had higher expression of CysLTR1 in the circulation and central nervous system (CNS)...
January 22, 2021: Immunology
Adham Fani Maleki, Giulia Cisbani, Nataly Laflamme, Paul Prefontaine, Marie-Michele Plante, Joanie Baillargeon, Manu Rangachari, Jean Gosselin, Serge Rivest
The significance of monocytes has been demonstrated in multiple sclerosis (MS). One of the therapeutic challenges is developing medications that induce mild immunomodulation that is solely targeting specific monocyte subsets without affecting microglia. Muramyl dipeptide (MDP) activates the NOD2 receptor, and systemic MDP administrations convert Ly6Chigh into Ly6Clow monocytes. Here, we report selective immunomodulatory and therapeutic effects of MDP on cuprizone and experimental autoimmune encephalomyelitis (EAE) mouse models of MS...
January 21, 2021: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
Alyssa E Johnson, Brian O Orr, Richard D Fetter, Armen J Moughamian, Logan A Primeaux, Ethan G Geier, Jennifer S Yokoyama, Bruce L Miller, Graeme W Davis
Missense mutations in Valosin-Containing Protein (VCP) are linked to diverse degenerative diseases including IBMPFD, amyotrophic lateral sclerosis (ALS), muscular dystrophy and Parkinson's disease. Here, we characterize a VCP-binding co-factor (SVIP) that specifically recruits VCP to lysosomes. SVIP is essential for lysosomal dynamic stability and autophagosomal-lysosomal fusion. SVIP mutations cause muscle wasting and neuromuscular degeneration while muscle-specific SVIP over-expression increases lysosomal abundance and is sufficient to extend lifespan in a context, stress-dependent manner...
January 21, 2021: Nature Communications
Salar Shareef, Seyed Omar Ebrahimi, Somayeh Reiisi
MicroRNAs (miRNAs) are a group of non-coding RNAs that play a role in gene regulation. Due to their possible functional importance, genetic variants within miRNA genes have been recognized as candidate biomarkers. Single-nucleotide polymorphisms (SNPs) in miRNA genes can be related to the risk of different autoimmune diseases. Some of these SNPs are rs2910164 in the miR-146a and rs1044165 in the miR-223. The aim of this study was to investigate the relationship between these polymorphisms and the risk of multiple sclerosis (MS) in an Iranian population...
January 21, 2021: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
Qin Ma, Alessandro Didonna
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) caused by complex gene-environment interactions. ATXN1 maps to 6p22.3, within the 233 loci associated with an increased risk of developing MS. Toxic gain-of-function mutations in ATXN1 cause the neurodegenerative disorder spinocerebellar ataxia type 1 (SCA1). Conversely, ATXN1 loss-of-function is involved in Alzheimer's disease (AD) and tumorigenesis. We have recently shown that ATXN1 exerts a protective immunomodulatory activity in the MS model experimental autoimmune encephalomyelitis (EAE)...
January 21, 2021: Molecular Brain
Francesco Corea, Silvia Ciotti, Antonella Cometa, Claudia De Carlo, Giancarlo Martini, Silvano Baratta, Mauro Zampolini
BACKGROUND: During the COVID-19 pandemic, the need for a broader implementation of telemedicine for many diseases has become apparent. Televisits are one type of telemedicine in which clinical visits are conducted remotely using an audio-visual connection with the patient at home. The use of televisits is more established in Stroke care but was also recently formally evaluated for Multiple Sclerosis (MS). This retrospective case series describes patient characteristics and reasons for televisits in persons with MS during the COVID-19 pandemic outbreak in Italy, which was declared in February 2020...
January 18, 2021: Neurology International
Larissa Carla de Paula Gois, Luciana Ramalho Pimentel-Silva, Benito Pereira Damasceno, Alfredo Damasceno
BACKGROUND: Cognitive impairment (CI) is present in all stages and subtypes of multiple sclerosis (MS). However, the majority of studies examined relapsing-remitting (RRMS) patients, and did not address cognitive phenotyping. Is still not clear whether patients with progressive MS (PMS) have a distinct pattern of CI compared to RRMS. In addition, there is conflicting data regarding the correlation between clinical and cognitive disability. OBJECTIVE: To investigate the differences of CI between PMS and RRMS patients, evaluating cognitive phenotypes...
December 19, 2020: Multiple Sclerosis and related Disorders
Jennifer Dunne, Hui Jun Chih, Andrea Begley, Alison Daly, Regina Gerlach, Robert Schütze, Emily Castell, Jean Byrne, Lucinda J Black
BACKGROUND: Practicing mindfulness may improve mental health and reduce pain in people with multiple sclerosis (MS). Since participating in face-to-face mindfulness programs can be challenging for people with MS, exploring alternative ways of delivering these programs is necessary. The objective of this trial was to assess feasibility of two different eight-week online mindfulness programs across five domains: recruitment, practicality, acceptability, integration of mindfulness practice, and limited efficacy testing on mental health, quality of life and pain...
December 29, 2020: Multiple Sclerosis and related Disorders
Joshua C Toliver, Jamie C Barner, Kenneth A Lawson, Karen L Rascati
BACKGROUND/OBJECTIVE: To compare algorithm determined disease severity, risk of multiple sclerosis (MS) relapse, and MS-related hospitalization between the age-eligible and disability-eligible MS Medicare populations. METHODS: Using the Humana claims dataset (2013 - 2015), patients were divided into Medicare age-eligible and disability-eligible groups. A previously developed algorithm, which used MS symptoms and healthcare utilization to categorize MS disease severity into three groups (low, moderate, high) at baseline was employed...
January 7, 2021: Multiple Sclerosis and related Disorders
Ann D Bass, Rafael Arroyo, Aaron L Boster, Alexey N Boyko, Sara Eichau, Carolina Ionete, Volker Limmroth, Carlos Navas, Daniel Pelletier, Carlo Pozzilli, Jennifer Ravenscroft, Livia Sousa, Mar Tintoré, Bernard M J Uitdehaag, Darren P Baker, Nadia Daizadeh, Zia Choudhry, David Rog
BACKGROUND: Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT00530348, NCT00548405), with sustained efficacy in 2 consecutive extensions (NCT00930553, NCT02255656 [TOPAZ]). METHODS: Post hoc analysis of 8-year alemtuzumab efficacy and safety in pooled CARE-MS patients (N=811) stratified by baseline age (≥18 to ≤25, >25 to ≤35, >35 to ≤45, >45 to ≤55 years). RESULTS: Compared with SC IFNB-1a over 2 years across age cohorts, alemtuzumab lowered annualized relapse rates (ARR; 0...
December 24, 2020: Multiple Sclerosis and related Disorders
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"